Blockade of the Activation of T Cells Around β-Cell by the Targeted CTLA-4 Ig at the Surface of β-Cell

被引：0

作者：

Qu, Wei ^{[1
]}

Li, Lin ^{[1
]}

Han, Chendong ^{[1
]}

Li, Meihua ^{[1
]}

Wang, Jing ^{[1
]}

Yin, Chaohui ^{[1
]}

Zhang, Jing ^{[2
]}

Jiang, Zhaoshun ^{[1
]}

机构：

[1] Jinan Mil Gen Hosp, Dept Endocrinol, Jinan 250031, Peoples R China

[2] Jinan Mil Gen Hosp, Dept Cadre Ward 3, Jinan 250031, Peoples R China

来源：

CELL BIOCHEMISTRY AND BIOPHYSICS | 2015年 / 71卷 / 02期

基金：

中国博士后科学基金;

关键词：

Diabetes; beta-Cell; CTLA-4-Ig; Targeting; ScFv; CONTROLLED-TRIAL; DOUBLE-BLIND; C-PEPTIDE; TYPE-1; IMMUNOTHERAPY; RESPONSES; MELANOMA;

D O I：

10.1007/s12013-014-0282-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Diabetes mellitus affects 347 million people worldwide, and over 80 % of diabetes deaths occur in low- and middle-income countries. Type 1 diabetes (T1D) is characterized by the attacks of the body's own immune system on the pancreatic beta-cells. In this work, we present a new CTLA-4 Ig targeting at the surface of beta-cell and prepare it from Escherichia coli aiming at clearing activated T cells around beta-cells and avoiding all-round decline in systematic immunity. This fusion protein is composed of CTLA-4-Ig part and beta-cell-targeting part, with properties of the therapeutic effect of CTLA-4-Ig and selective binding to beta-cells. In preliminary biological activity assay, our results verified the feasibility of beta-cell-targeting strategy and its activity of CTLA-4-Ig part. The fusion protein recognizes and binds specifically to CD80(+) and CD86(+) cells as well as beta-cell, but not to control cells, displaying the potential to be used as a feasible and effective treatment of T1D with lessened side effect.

引用

页码：913 / 918

页数：6

共 24 条

[1] Type 1 diabetes: new perspectives on disease pathogenesis and treatment [J].

Atkinson, MA ;

Eisenbarth, GS .

LANCET, 2001, 358 (9277) :221-229

[2] Comparable Ascertainment of Newly-Diagnosed Atrial Fibrillation Using Active Cohort Follow-Up versus Surveillance of Centers for Medicare and Medicaid Services in the Atherosclerosis Risk in Communities Study [J].

Bengtson, Lindsay G. S. ;

Kucharska-Newton, Anna ;

Wruck, Lisa M. ;

Loehr, Laura R. ;

Folsom, Aaron R. ;

Chen, Lin Y. ;

Rosamond, Wayne D. ;

Duval, Sue ;

Lutsey, Pamela L. ;

Stearns, Sally C. ;

Sueta, Carla ;

Yeh, Hsin-Chieh ;

Fox, Ervin ;

Alonso, Alvaro .

PLOS ONE, 2014, 9 (04)

[3] Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function [J].

Boni, Andrea ;

Cogdill, Alexandria P. ;

Dang, Ping ;

Udayakumar, Durga ;

Njauw, Ching-Ni Jenny ;

Sloss, Callum M. ;

Ferrone, Cristina R. ;

Flaherty, Keith T. ;

Lawrence, Donald P. ;

Fisher, David E. ;

Tsao, Hensin ;

Wargo, Jennifer A. .

CANCER RESEARCH, 2010, 70 (13) :5213-5219

[4] Biologic therapies in type 1 diabetes: how far are they from us? [J].

Deng Chao ;

Xiang Yu-fei ;

Zhou Zhi-guang .

CHINESE MEDICAL JOURNAL, 2013, 126 (21) :4003-4005

[5] CTLA-4: new insights into its biological function and use in tumor immunotherapy [J].

Egen, JG ;

Kuhns, MS ;

Allison, JP .

NATURE IMMUNOLOGY, 2002, 3 (07) :611-618

[6] Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification [J].

Guo, Jun ;

Si, Lu ;

Kong, Yan ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Zhu, Yanyan ;

Corless, Christopher L. ;

Li, Li ;

Li, Haifu ;

Sheng, Xinan ;

Cui, Chuanliang ;

Chi, Zhihong ;

Li, Siming ;

Han, Mei ;

Mao, Lili ;

Lin, Xuede ;

Du, Nan ;

Zhang, Xiaoshi ;

Li, Junling ;

Wang, Baocheng ;

Qin, Shukui .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2904-2909

[7] Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes [J].

Hagopian, William ;

Ferry, Robert J., Jr. ;

Sherry, Nicole ;

Carlin, David ;

Bonvini, Ezio ;

Johnson, Syd ;

Stein, Kathryn E. ;

Koenig, Scott ;

Daifotis, Anastasia G. ;

Herold, Kevan C. ;

Ludvigsson, Johnny .

DIABETES, 2013, 62 (11) :3901-3908

[8] Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial [J].

Herold, K. C. ;

Gitelman, S. E. ;

Willi, S. M. ;

Gottlieb, P. A. ;

Waldron-Lynch, F. ;

Devine, L. ;

Sherr, J. ;

Rosenthal, S. M. ;

Adi, S. ;

Jalaludin, M. Y. ;

Michels, A. W. ;

Dziura, J. ;

Bluestone, J. A. .

DIABETOLOGIA, 2013, 56 (02) :391-400

[9] Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity [J].

Jain, Nitya ;

Nguyen, Hai ;

Chambers, Cynthia ;

Kang, Joonsoo .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (04) :1524-1528

[10] Construction and Characterization of a CTLA-4-Targeted scFv-Melittin Fusion Protein as a Potential Immunosuppressive Agent for Organ Transplant [J].

Jin, Hailong ;

Li, Congran ;

Li, Ding ;

Cai, Ming ;

Li, Zhouli ;

Wang, Shuang ;

Hong, Xin ;

Shi, Bingyi .

CELL BIOCHEMISTRY AND BIOPHYSICS, 2013, 67 (03) :1067-1074

← 1 2 3 →